MAIA Biotechnology Files 8-K on Shareholder Vote Matters

Ticker: MAIA · Form: 8-K · Filed: May 29, 2024 · CIK: 1878313

Maia Biotechnology, INC. 8-K Filing Summary
FieldDetail
CompanyMaia Biotechnology, INC. (MAIA)
Form Type8-K
Filed DateMay 29, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

TL;DR

MAIA Bio filed an 8-K for shareholder vote matters. Expect updates soon.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on May 29, 2024, reporting on a submission of matters to a vote of security holders. The filing date for the earliest event reported is May 24, 2024. The company is incorporated in Delaware and its principal executive offices are located in Chicago, IL.

Why It Matters

This filing indicates that MAIA Biotechnology is seeking or has received approval from its shareholders on specific corporate actions, which could impact the company's future direction and governance.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes can sometimes precede significant corporate actions or changes that may affect stock price.

Key Players & Entities

FAQ

What specific matters were submitted for a vote of security holders?

The filing states it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters within the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 24, 2024.

What is the principal executive office address for MAIA Biotechnology, Inc.?

The principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.

Under which section of the Securities Exchange Act is this 8-K filed?

This Current Report is filed Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

What is the SIC code for MAIA Biotechnology, Inc.?

The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 612 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-05-29 16:05:58

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 29, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing